Argenx announces positive topline results from adapt seron study of vyvgart in patients with achr-ab seronegative gmg

Study met primary endpoint (p-value=0.0068) first global phase 3 study to demonstrate clinically meaningful improvements in disease activity across all three subtypes – musk+, lrp4+, triple seronegative supplemental biologics license application (sbla) to be submitted to u.s. food and drug administration (fda) by end of 2025 august 25, 2025, 7:00 am cet amsterdam, the netherlands – argenx se (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced positive topline data from the pivotal adapt seron study of vyvgart® (iv: efgartigimod alfa-fcab). the study met its primary endpoint (p-value=0.0068), demonstrating that achr-ab seronegative gmg patients treated with vyvgart achieved a statistically significant and clinically meaningful improvement in mg-adl (myasthenia gravis activities of daily living) total score compared to placebo.
ARGX Ratings Summary
ARGX Quant Ranking